anticoagulant, curative dose in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias deathsdetailed results ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 0.88 [0.64; 1.20]
COALIZAO ACTION, 2021 1.55 [0.90; 2.70]
COVID-PACT, 2022 0.91 [0.56; 1.48]
REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 1.08 [0.85; 1.38]
1.03 [0.85 ; 1.25 ] ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021, COALIZAO ACTION, 2021, COVID-PACT, 2022, REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 4 16% 4,320 moderate not evaluable clinical deteriorationdetailed results COALIZAO ACTION, 2021 1.35 [0.85; 2.15]
1.35 [0.85 ; 2.15 ] COALIZAO ACTION, 2021 1 0% 615 NA not evaluable clinical improvementdetailed results REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 0.83 [0.67; 1.03]
0.83 [0.67 ; 1.03 ] REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 1 0% 1,074 NA not evaluable clinical improvement (28-day)detailed results ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 1.27 [1.03; 1.57]
1.27 [1.03 ; 1.57 ] ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 1 0% 2,219 NA not evaluable death or ventilationdetailed results ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 0.82 [0.63; 1.07]
0.82 [0.63 ; 1.07 ] ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 1 0% 2,231 NA not evaluable Major thrombotic events or deathdetailed results COVID-PACT, 2022 0.56 [0.32; 0.98]
REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 1.04 [0.80; 1.36]
0.80 [0.44 ; 1.46 ] COVID-PACT, 2022, REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 2 73% 1,473 moderate not evaluable Major bleedingdetailed results ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 1.80 [0.88; 3.67]
COALIZAO ACTION, 2021 2.50 [0.78; 8.06]
COVID-PACT, 2022 3.86 [0.44; 34.07]
REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 1.48 [0.74; 2.98]
1.80 [1.15 ; 2.82 ] ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021, COALIZAO ACTION, 2021, COVID-PACT, 2022, REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 4 0% 4,314 moderate not evaluable Thromboembolic eventsdetailed results COALIZAO ACTION, 2021 0.73 [0.41; 1.29]
0.73 [0.41 ; 1.29 ] COALIZAO ACTION, 2021 1 0% 614 NA not evaluable 0.5 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-11-01 00:01 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 830
- roots T: 290
